Healthy Subjects Clinical Trial
Official title:
Scintigraphic Assessment of Nasal Deposition and Clearance of 99mTc DTPA Ketorolac Solution Administered Using the Valois Nasal Spray Device
Verified date | February 2017 |
Source | Egalet Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This was a randomised three-way crossover design study. The study consisted of three study
periods each separated by a minimum 44 hour washout period. During the course of each study
period, scintigraphic images were acquired at planned intervals after dosing. Subjects were
able to leave the clinical unit after the completion of study specific procedures at 6 hours
post-dose.
The primary objective of the study was to determine whether any of the radiolabelled
ketorolac formulation was deposited in the lungs of healthy volunteers following nasal
inhalation under three different conditions (gentle sniff-inhalation with subject standing,
vigorous sniff-inhalation with subject standing, gentle sniff-inhalation with subject
semi-supine). The secondary objectives were to determine the deposition pattern of
radiolabelled ketorolac solution in the nasal cavity, and clearance of the radiolabel over a
six-hour period.
Status | Completed |
Enrollment | 13 |
Est. completion date | December 2002 |
Est. primary completion date | October 2002 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Healthy males or non-pregnant, non-lactating, surgically sterile or post-menopausal females (post-menopausal was defined as > 2 years post-last period and more than 50 years of age), or using an acceptable form of contraception as defined in section 9.3.2 (g) - Aged 18-65 years - Body Mass Index of between 18 and 30 kg/m2 Exclusion Criteria: - Participation in a clinical research study involving investigational drugs or dosage forms within the previous 4 months - Subjects who had sought advice from their GP or consulted a counsellor for abuse or misuse of alcohol, non-medical, medicinal drugs, or other substance-abuse such as solvents. Any current or past use of Class A drugs such as opiates, ecstasy, LSD, and amphetamines (Class B). Volunteers that admitted to past use of cannabis were not excluded as long as they had a negative drugs of abuse test and had been abstinent for at least 12 months - Positive drugs of abuse test result - Regular alcohol consumption in males >21 units per week and females >14 units per week. (one unit of alcohol was defined as 0.5 pint (280 ml) of beer or cider, 1 glass (125 ml) wine, 1 glass (70 ml) of sherry or port, 1 measure (25 ml) of whisky, brandy or rum. For low alcohol drinks, one unit of alcohol was defined as 2 glasses (250 ml) of low alcohol wine and 5 half pints (840 ml) of low alcohol beer) - Current smokers, i.e. those who had smoked within the last 12 months - A breath carbon monoxide reading of greater than 10 ppm either at the pre-study medical examination or on a study day prior to dosing - Females of child bearing potential who were sexually active and either not surgically sterile, post-menopausal or not using a form of acceptable contraceptive (contraceptive pills/injection, condoms with spermicide, IUCDs (coils) and diaphragms with spermicide (only if the woman was 35 or more) or abstinence - Radiation exposure from clinical trials, including that from the present study and from diagnostic X-rays but excluding background radiation, exceeding 5 mSv in the last twelve months or 10 mSv in the last five years. No subject whose occupational exposure is monitored will participate in the study - Clinically significant abnormal biochemistry, haematology or urinalysis - Screening FEV1 < 80% of the predicted value for their age, sex, height and race - History of chronic respiratory disorders or bronchospasm - History of adverse reaction or allergy to ketorolac or di-sodium EDTA - History of severe or multiple allergies, including hayfever and perennial rhinitis - History of adverse reaction or allergy to aspirin or any other non-steroidal anti inflammatory drug (e.g., ibuprofen, flurbiprofen, ketoprofen or diclofenac) - History of infantile bronchiolitis, or a history or the presence of asthma, or wheezy respiration, hayfever and perennial rhinitis - History of nasal fracture, nasal deformity or nasal polyps - History of disease, surgery, or abnormality of the upper respiratory tract, especially the nasal cavity - History of significant nose bleeds - Sinusitis within four weeks of the first study period - Nasal jewelry or nasal piercings - Subjects using topical nasal medication e.g. decongestants, within 14 days prior to the first dosing day - Upper respiratory tract infection (excluding otitis media) within 14 days of the first study day, or lower respiratory tract infection within the previous 3 months - Subjects taking any medication that might affect the respiratory tract within 14 days of the first study day - Non-prescription and prescription medication (including vitamins and natural or herbal remedies eg. St Johns Wort) within 14 days of the first study day (oral contraceptives, contraceptive implants or depot injections, intra-uterine devices with hormonal implants, Hormone Replacement Therapy (HRT) and occasional paracetamol (up to 4 g daily) were permitted) - History of peptic ulceration or gastrointestinal bleeding - History of kidney disease - History of clotting disorders - Failure to satisfy the Principal Medical Investigator of fitness to participate for any other reason |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Pharmaceutical Profiles, Ltd | Ruddington | Nottingham |
Lead Sponsor | Collaborator |
---|---|
Egalet Ltd |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Scintigraphic images of radiolabeled ketorolac solution entering the lungs and subsequently being cleared from the lungs following administration to the nostrils using a Valois nasal device. | Change from baseline to immediately post-dose, 10, 20, 30, 45, and 60 minutes and 2, 4, and 6 hours post dose | ||
Secondary | Scintigraphic assessment of the deposition pattern of radiolabeled ketorolac solution in the nasal cavity, nasopharynx, esophagus, and stomach. | Change from baseline to immediately post-dose, 10, 20, 30, 45, and 60 minutes and 2, 4, and 6 hours post dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |